氨溴索联合布地奈德治疗对小儿喘息性支气管炎临床疗效、炎性因子及免疫功能的影响

The effect of ambroxol combined with budesonide on the clinical efficacy,inflammatory factors and immune function of children with asthmatic bronchitis

目的探讨氨溴索联合布地奈德治疗对小儿喘息性支气管炎临床疗效、炎性因子及免疫功能的影响。方法2017年1月至2019年1月我院收治的104例喘息性支气管炎患儿,根据治疗方法不同分为观察组50例,采用盐酸氨溴索联合布地奈德悬浊液治疗,对照组54例,采用盐酸氨溴索治疗。对比两组患者治疗1周后,临床疗效、炎性因子水平、免疫细胞水平情况及两组患儿治疗后临床症状改善时间、肺功能指标,用药过程中不良反应发生情况。结果观察组治疗总有效率96.00%显著高于对照组81.48%(P<0.05);治疗后,两组CD4+水平与CD4^(+)/CD8^(+)升高,CD8^(+)水平降低,且两组间比较差异有统计学意义(P<0.05);观察组IL-4、IL-6、IL-10、呼吸阻力(RR)、呼气峰流速(PEF)低于对照组,IFN-γ、潮气量(TV)水平高于对照组(P<0.05);气促、咳嗽、喘鸣音及肺部啰音改善时间明显短于对照组(P<0.05);两组患儿不良反应总发生率比较差异无统计学意义(P>0.05)。结论氨溴索联合布地奈德治疗小儿喘息性支气管炎具有较高的治疗疗效,可改善患儿机体免疫功能、炎性症状,有效缓解临床症状,临床应用前景广阔。

Objective To explore the effect of ambroxol combined with budesonide on the clinical efficacy,inflammatory factors and immune function of children with asthmatic bronchitis.Methods One hundred and four children with asthmatic bronchitis admitted to our hospital from January 2017 to January 2019 were selected.According to different treatment methods,they were divided into observation group(n=50)treated with ambroxol hydrochloride combined with budesonide suspension,and control group(n=54)treated with ambroxol hydrochloride.After 1 week of treatment,the clinical efficacy,inflammatory factor levels,immune cell levels,improvement time of clinical symptoms,lung function indexes and adverse reactions during the treatment were compared between the two groups.Results The total effective rate of treatment in the observation group was 96.00%,which was significantly higher than 81.48%in the control group(P<0.05).After treatment,the levels of CD4^(+)and CD4^(+)/CD8^(+)in the two groups were increased while the level of CD8^(+)was decreased,and the difference between the two groups was statistically significant(P<0.05).After treatment,the levels of IL-4,IL-6,IL-10,RR and PEF were significantly lower and the levels of IFN-γand TV were significantly higher in the observation group than those of the control group(P<0.05).The improvement time in shortness of breath,cough,wheezing and pulmonary rales in the observation group was significantly shorter than that in the control group(P<0.05).There was no difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Ambroxol combined with budesonide has higher therapeutic effect in the treatment of asthmatic bronchitis in children.It can improve the immune function and inflammatory symptoms of children.Therefore,It can effectively relieve the clinical symptoms and has a broad prospect in clinical application.